Buzz Stocks: Wynn Resorts, Limited, AbbVie Inc, and Seres Therapeutics Inc

Today's stocks to watch in the news include Wynn Resorts, Limited (NASDAQ:WYNN), AbbVie Inc (NYSE:ABBV), and Seres Therapeutics Inc (NASDAQ:MCRB)

Jul 29, 2016 at 10:20 AM
facebook X logo linkedin


U.S. stocks are down after a couple of blue-chip earnings misses, and as traders react to weaker-than-expected preliminary gross domestic product (GDP) data. Among equities in focus today are casino stock Wynn Resorts, Limited (NASDAQ:WYNN), as well as biotechs AbbVie Inc (NYSE:ABBV) and Seres Therapeutics Inc (NASDAQ:MCRB).  

  • WYNN is down 7.6% at $96.75, despite reporting earnings that beat analyst expectations. Instead, traders are reacting to the casino's smaller-than-expected allocation of table permits for a new casino in Macau. This news led to a subsequent slew of bearish analyst notes, including a downgrade to "underperform" by CSLA. Nomura cut its rating on WYNN to "reduce" from "neutral," trimmed its price target to $83 from $92, and said "This paltry allocation is a clear message from Beijing that it is serious about Macau enforcing the table cap." Despite the drop, WYNN remains up over 50% year-to-date, although the shares have been running into resistance at the $104-$105 area. WYNN's Schaeffer's put/call open interest ratio (SOIR) of 0.54 sits at the very bottom of its 52-week range, suggesting short-term option players haven't been more call-skewed in the last 12 months.
  • ABBV is up 1.6% at $65.75, after another earnings beat and upwardly revised full-year forecast, citing strong drug sales, especially for its rheumatoid arthritis drug, Humira. This puts AbbVie Inc up nearly 10% since the beginning of 2016, and the shares are now flirting with year-to-date highs. Analysts remain skeptical of ABBV, however, with seven of 13 rating the shares a "hold" or worse, leaving plenty of room for potential upgrades to propel the shares even higher.
  • MCRB is down 76.2% at $8.53 -- a new all-time low – after its experimental drug, SER-109, failed to reach its main goal in a mid-stage study. Nevertheless, H.C. Wainwright subsequently began coverage on MCRB with a "buy" rating and optimistic price target of $50 -- a 486% premium to the stock's new low. MCRB now sits 75% lower year-to-date, and today finds itself on the short-sale restricted list. There are likely plenty of shorts cheering, though, as short interest represents nearly two-and-a-half weeks of pent-up buying demand, at MCRB's average daily volume. 

Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI